Levodopa prodrugs, and compositions and uses thereof

Details Levodopa prodrugs, and compositions and uses thereof Levodopa prodrugs, and compositions and uses thereof

2011-06-07

2011-06-07

Puttlitz, Karl J (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acid esters

C560S019000, C560S037000, C560S038000

Reexamination Certificate

active

07956212

ABSTRACT:
Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.

REFERENCES:
patent: 3811444 (1974-05-01), Heller et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4038411 (1977-07-01), Saari
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4093709 (1978-06-01), Choi et al.
patent: 4134991 (1979-01-01), Wermuth
patent: 4180509 (1979-12-01), Metcalf et al.
patent: 4311706 (1982-01-01), Bodor et al.
patent: 4663349 (1987-05-01), Repta
patent: 4771073 (1988-09-01), Repta
patent: 4826875 (1989-05-01), Chiesi
patent: 4873263 (1989-10-01), Repta
patent: 4914222 (1990-04-01), Budavari et al.
patent: 4966915 (1990-10-01), Tsuchiya et al.
patent: 4983400 (1991-01-01), Dempski et al.
patent: 5017607 (1991-05-01), Chiesi
patent: 5057321 (1991-10-01), Edgren et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5128145 (1992-07-01), Edgren et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5190763 (1993-03-01), Edgren et al.
patent: 5283352 (1994-02-01), Backstrom et al.
patent: 5332576 (1994-07-01), Mantelle
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5607969 (1997-03-01), Milman et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5827819 (1998-10-01), Yatvin et al.
patent: 5840756 (1998-11-01), Cohen et al.
patent: 6696600 (2004-02-01), Frenkel et al.
patent: 7101912 (2006-09-01), Xiang et al.
patent: 7144877 (2006-12-01), Gallop et al.
patent: 7323585 (2008-01-01), Xiang et al.
patent: 7342131 (2008-03-01), Xiang et al.
patent: 7534813 (2009-05-01), Xiang et al.
patent: 7563821 (2009-07-01), Xiang et al.
patent: 2002/0099041 (2002-07-01), Gallop et al.
patent: 2003/0152628 (2003-08-01), Licht et al.
patent: 2003/0158254 (2003-08-01), Zerangue et al.
patent: 2005/0209181 (2005-09-01), Akil et al.
patent: 2005/0282891 (2005-12-01), Xiang et al.
patent: 2006/0020028 (2006-01-01), Xiang et al.
patent: 2007/0225366 (2007-09-01), Xiang et al.
patent: 2008/0070984 (2008-03-01), Tran et al.
patent: 2008/0103200 (2008-05-01), Xiang et al.
patent: 2008/0132570 (2008-06-01), Xiang et al.
patent: 2008/0171789 (2008-07-01), Xiang et al.
patent: 2008/0214663 (2008-09-01), Xiang et al.
patent: 2009/0156679 (2009-06-01), Xiang et al.
patent: 2 607 198 (2006-11-01), None
patent: 102005022276 (2006-11-01), None
patent: 0 309 827 (1992-01-01), None
patent: 1447599 (1976-08-01), None
patent: 1537951 (1979-01-01), None
patent: 58-024547 (1983-02-01), None
patent: WO 86/04579 (1986-08-01), None
patent: WO 88/01615 (1988-03-01), None
patent: WO 01/68065 (2001-09-01), None
patent: WO 02/28882 (2002-04-01), None
patent: WO 2007/087256 (2007-08-01), None
Database CAS citation 1994:701312 [retrieved Nov. 23, 2009] from STN; Columbus, OH USA.
Database CAS citation 1995:365090 [retrieved Nov. 23, 2009] from STN; Columbus, OH USA.
Rouhi, C&E News Feb. 2003, pp. 32-35.
http://www.chem.uky.edu/Courses/che232/JEA/In/9.%20Esters—etc.pdf, retrieved Mar. 24, 2010 (Carboxylic Acid Derivatives and Nitriles).
Database CAS citation 1978:444225 [retrieved Mar. 24, 2010] from STN; Columbus, OH, USA.
Garzon-Abureh et al., J. Med. Chem., 1986, 29, 687-691.
Notice of Allowance mailed Mar. 20, 2009 for U.S. Appl. No. 11/634,354, filed Dec. 4, 2006.
Notice of Allowance mailed May 29, 2009 for U.S. Appl. No. 12/001,618, filed Dec. 11, 2007.
Office Action mailed Aug. 7, 2009 for U.S. Appl. No. 12/005,117, filed Dec. 20, 2007.
Supplemental Notice of Allowability mailed Jan. 23, 2008 for U.S. Appl. No. 11/145,159, filed Jun. 3, 2005.
Office Action mailed Jan. 25, 2010 for U.S. Appl. No. 12/005,120, filed Dec. 20, 2007.
Alpert and Friedhoff, Paradoxical reaction to L-dopa in schizophrenic patients,Am J Psychiatry1978, 135(11), 1329-1332.
Bai, pGlu-L-Dopa-Pro: A Tripeptide Prodrug Targeting the Intestinal Peptide Transporter for Absorption and Tissue Enzymes for Conversion.Pharm. Res. 1995, 12(7), 1101-1104.
Betarbet et al.,Bioessays2002, 24(4), 308-18.
Berg et al., Pharmaceutical Salts,J. Pharm. Sci. vol. 66, No. 1, Jan. 1977, 19 pages.
Bodor et al., Improved Delivery through Biological Membrane's. 4. Prodrugs of L-Dopa.J. Med. Chem. 1977, 20(11):1435-1445.
Boivin and Montplaisir, The effects of L-dopa on excessive daytime sleepiness in narcolepsy.Neurology1991, 41:1267-1269.
Bonelli and Wenning, Pharmacological Management of Huntington's disease: an evidence-based review,Current Pharmaceutical Design2006, 12(21), 2701-2720.
Bruno and Bruno, Effects of L-dopa on pharmacological parkinsonism,Acta Psychiatr Scand1966, 4(3), 264-271.
Buchanan et al., Double blind trial of L-dopa in chronic schizophrenia,.Aust N Z J Psychiatry1975, 9(4), 269-271.
Cho et al.,Biochem. Biophys. Res. Commun2006, 341, 6-12.
Coleman et al., “A practical guide to polymer miscibility,”Polymer1990, 31, 1187-1203.
Conti et al., Levodopa for idiopathic restless legs syndrome: evidence-based review,Mot Disord2007, 22(13), 1943-1951.
Cools, Dopaminergic modulation of cognitive function-implications for L-dopa treatment in Parkinson's disease.Neuroscience Biobehavioral Rev2006, 30, 1-23.
Cooper et al., L-Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.J. Pharm. Pharmacol. 39:627-635 (1987).
Di Stefano et al., Dimeric L-Dopa Derivatives as Potential Prodrugs.Bioorganic&Medicinal Chem. Lett. 11:1085-1088 (2001).
Doggrell, 2002, “The therapeutic potential of dopamine modulators on the cardiovascular and renal systems,”Expert Opin. Investig. Drugs, 11(5):631-644.
Durif et al., Mov Disord 1999, 14, 242-245.
During et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,”Ann. Neurol. 25(4):351-356 (1989).
Ebadi and Srinivasan, Pathogenesis, prevention and treatment of neuroleptic-induced movement disorders, Pharmacological Reviews 1995, 47(4), 575-604.
Eltayb et al., Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjuncitve low-dose L-dopa.Biol Psychiatry2005, 58, 337-343.
Emborg, J. Neuro. Meth. 2004, 139, 121-143.
Fahn et al., Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351(24), 2498-2508.
Faulkner et al., Ann. Pharmacother. 2003, 37(2), 282-6.
Fincher, J., “Particle Size of Drugs and Its Relationship to Absorption and Activity,”J. Pharm. Sci. 57(11):1825-1835 (1968).
Fix et al, Short-Chain Alkyl Esters of L-Dopa as Prodrugs for Rectal Absorption.Pharm. Res.1989, 6(6), 501-505.
Fix et al., A Comparison of Oral and Rectal Absorption of L-Dopa Esters in Rats and Mice.Pharm. Res. 1990, 7(4), 384-387.
Floel et al., Dopaminergic effects on encoding of a motor memory in chronic stroke,Neurology2005, 65(3), 472-474.
Floel et al., Levodopa increases memory encoding and dopamine release in the striatum in the elderly,Neurobiology of Aging2006, PMID 17098331.
Folstein et al.,J Psychiatr Res1975, 12, 189-198.
Garzon-Aburbeh et al., A Lymphotropic Prodrug of L-Dopa: Synthesis, Pharmacological Properties, and Pharmacokinetic Behavior of 1,3-Dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]propane-1,2,3-triol.J. Med. Chem. 1986, 29, 687-691.
Gelb et al.,Arch Neurol1999, 56(1), 33-9.
Gerlach and Luhdorf, The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs.Psychopharmacologia1975, 44(1), 105-110.
Gibb et al.,J Neurol Neurosurg Psychiatry1988, 51, 745-752.
Giovanni et al.,J Neurol Neurosurg Psychiatry1999, 67, 624-629.
Hirsch et al., J Neural Transm Suppl 2003, 65, 89-100.
Hisaka et al., Absorption of a Novel Prodrug of L-Dopa, L-3-(3-Hydroxy-4-Pivaloyloxyphenyl)alanine (NB-355): In Vitro and In Situ Studies,.Drug Metabolism and Disposition 1990, 18(5), 621-625.
Hogl et al., Increased daytime sleepiness in Parkinson's disease:

Affiliated with

Also associated with

Rating

Levodopa prodrugs, and compositions and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Levodopa prodrugs, and compositions and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Levodopa prodrugs, and compositions and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2619397